Endocrine-Related Cancer

@endocancer.bsky.social

55 Followers 119 Following

Publishing translational & clinical investigations of human health & disease focusing on #endocrine neoplasias & hormone-dependent #cancers. Owned by Society of Endocrinology.

Editorial Opportunity Deputy Editor of Endocrine-Related Cancer Endocrine-Related Cancer logo
Endocrine-Related Cancer logo. Hormone secretion predicts poor prognosis in lung neuroendocrine neoplasms Ieva Lase, Eir Löfgren, Agnes Hegedus, Malin Grönberg, Staffan Welin, Eva Tiensuu Janson. Figure 1. Representative pictures from immunohistochemical staining of serotonin and calcitonin in neuroendocrine neoplasms of the lung (typical carcinoids). Tumour positive for serotonin (A) and calcitonin (C). Tumour negative for serotonin (B) and calcitonin (D). Total magnification: 100×, scale bar: 100 μm. Endocr Relat Cancer (2026) 33 (6): e260142. doi.org/10.1530/ERC-26-0142. Published by Bioscientifica logo. 80 Years 1946-2026 Society for Endocrinology logo.
Endocrine-Related Cancer logo. Emerging Leader 2026 Rayzel C Fernandes Division of Cancer, Imperial Centre for Translational & Experimental Medicine, Imperial College London, London, UK Figure 1. Factors influencing altered AR binding and cistrome reprogramming in prostate cancer. The AR cistrome can be altered by a multitude of factors, from somatic mutations in AREs to overexpression of enhancer-associated proteins, as well as AR amplification and splice variants, changes in epigenetic coregulators, disruption of 3D genomic organization, and alterations in transcriptional activity by long noncoding RNAs (lncRNAs). Figure 1 in Endocr Relat Cancer (2026) 33 (6): e250529. doi.org/10.1530/ERC-25-0529.
Endocrine-Related Cancer logo. By Malin Hagberg Thulin et al. Figure 1. Tumor-induced bone response in orchiectomized (ORX) and orchiectomized plus adrenalectomized (ORX + ADX) mice at termination. (A) Experimental setup. (B) Bone mineral density (BMD), measured by dual-energy X-ray (DEXA), of the tibia in ORX mice injected with VCaP, 22Rv1, and LNCaP tumor cells (T) and sham-injected control tibia (C) of the same mice. (C) Ratio of the BMD measured in the tumor cell-injected tibia (T) to the sham-injected control tibia (C) in ORX and ORX + ADX mice injected with VCaP, 22Rv1, and LNCaP tumor cells. ORX mice are indicated by green squares, and ORX + ADX mice are indicated by blue dots. (D) Representative μCT images of the sham-injected tibia (control) and VCaP-injected tibia (tumor) in ORX and ORX + ADX mice...Endocrine-Related Cancer 33, 6; 10.1530/ERC-25-0309. Published by Bioscientifica logo. 80 Years 1946-2026 Society for Endocrinology logo.
Endocrine-Related Cancer logo. Open Access logo. The role of stem cells in pituitary tumour formation. By James Kaufman-Cook, Bence Kövér, and Cynthia L Andoniadou. Figure 3. Stem cell models of pituitary tumourigenesis. Schematic illustrating the potential roles of PSCs and TSC-like cells in tumour formation. Under oncogenic stimuli, stem cells can drive tumourigenesis through cell-autonomous mechanisms by proliferating rapidly, differentiating and directly giving rise to tumours, in a classic cancer stem cell (CSC) paradigm (purple box). Thus far, this has been demonstrated in SOX2+ cells harbouring mutations in BRAFV600E in human PCP. Tumourigenesis can also occur via non-cell-autonomous mechanisms (yellow box), where paracrine signals or a senescence-associated secretory phenotype from a transformed tumour-initiating cell (TIC) promotes proliferation and/or transformation of other cells into TSCs or TSC-like cells. Thus far, this has been demonstrated only in ACP. Whether TSC-like cells contribute to tumourigenesis through either cell-autonomous or non-cell-autonomous mechanisms in pituitary neuroendocrine tumours (PitNETs) remains to be determined. PSCs exposed to oncogenic stimuli that become lineage-committed may retain stem-like characteristics, marker expression or proliferative potential, contributing to tumour formation as TSCs. Conversely, and still unconfirmed, committed endocrine cells may undergo de-differentiation in response to oncogenic signals, acquiring stem-like properties and promoting tumourigenesis through either cell-autonomous or non-cell-autonomous pathways, as TSCs. These populations may also influence tumour progression by modulating the tumour microenvironment. Finally, healthy PSCs may become trapped within the expanding tumour mass and contribute to tumour maintenance or progression through... Endocrine-Related Cancer 33, 6; 10.1530/ERC-26-0171. Published by Bioscientifica logo. 80 Years 1946-2026 Society for Endocrinology logo.
Emerging Leader 2025. J. (Hans) Hofland, MD. ENETS Center of Excellence, Section of Endocrinology, Department of Internal Medicine, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands. Endocrine-Related Cancer logo. PDF screenshot of 'Gut microbial and functional alterations lead to metagenomic signatures for midgut neuroendocrine tumor patients and for carcinoid syndrome'
Endocrine-Related Cancer logo. Phaeochromocytomas and paragangliomas harbour tumour-initiating SOX2+ stem cells. By Yasmine Kemkem et al. Open Access logo. Figure 1.Immunohistochemistry using antibodies against SOX2 on FFPE sections of phaeochromocytomas and paragangliomas (PPGLs). In all panels, cells immunopositive for SOX2 are in brown, cells counterstained with haematoxylin. (A) Negative control staining without primary antibody. (B) Non-metastatic phaeochromocytomas PCC1 to PCC3 with mutations in NF1. (C) Non-metastatic phaeochromocytoma PCC4 with mutation in SDHC. (D) Non-metastatic phaeochromocytomas PCC5 to PCC7 with mutations in RET. (E) Malignant paraganglioma PGL8 and non-malignant phaeochromocytoma PCC9 with mutations in VHL. (F) Non-malignant paragangliomas PGL12 to PGL14 and malignant paragangliomas PGL15 to PGL17...Endocrine-Related Cancer 33, 5; 10.1530/ERC-25-0242 Published by Bioscientifica logo. 80 Years 1946-2026 Society for Endocrinology logo.
Emerging Leader 2026. Katherine I. Wolf, MD Department of Internal Medicine, Division of Metabolism, Endocrinology, & Diabetes, Endocrine Oncology Program, Michigan Medicine, Ann Arbor, Michigan, USA PDF of Adrenocortical carcinoma as a manifestation of Birt–Hogg–Dubé syndrome in Endocrine-Related Cancer. Endocrine-Related Cancer logo.
Endocrine-Related Cancer logo. New Research. Breast cancer metastasis in obesity: extracellular vesicles as drivers. By Isadora Ramos-Andrade et al. Published by Bioscientifica logo. Society for Endocrinology logo.
Endocrine-Related Cancer logo. Open-Access logo. Reproductive and sexual sequelae of neuroendocrine tumour therapies: an under-recognised challenge. By Kalyan Mansukhbhai Shekhda et al. Figure 3. Complex interplay of neuroendocrine tumours, their treatment, and psychosocial health on sexual dysfunction in patients with NETs. Endocrine-Related Cancer 33, 4; 10.1530/ERC-25-0500. Published by Bioscientifica logo. 80 Years 1946-2026 Society for Endocrinology logo.
Pituitary Tumours: Scientific Discoveries, Clinical Advances and Contested Paradigms Special Collection. New Review. DNA methylation and demethylation dynamics in pituitary neuroendocrine tumours. By Borbála Szabó, Attila Patócs, Henriett Butz. Endocrine-Related Cancer logo. 80 Years 1946-2026 Society for Endocrinology logo.
Endocrine-Related Cancer logo. RET@Thirty: Three Decades of Remarkable Progress. Special Collection. New Review: RET receptor tyrosine kinase architecture, assemblies, and activation. By Kate Newbold and Leslie Cheng. Figure 1. Figure 1 (A) Schematic representation of human RET sequence highlighting modules, individual domains, calcium-binding sites, autophosphorylation sites, and their downstream effectors and corresponding residue numberings. The two abundant RET isoforms, RET9 and RET51, extend to residue 1072 or 1114, respectively. RET51 is unique in containing the Y1096 site for binding to Grb2. (B) Overview of the three-dimensional structure of the human RET-ECM (left panel), with domain colours coded according to panel (A), indicating the location of binding sites, and the human RET-ICM in the unphosphorylated state (right panel). The RET-ECM structure is a predicted model using AlphaFold3 (60), and the RET-ICM model...Endocrine-Related Cancer 33, 4; 10.1530/ERC-25-0322
Endocrine-Related Cancer logo. 80 Years 1946-2026 Society for Endocrinology logo. Best Paper. Emerging Leaders 2025 Special Collection. "Evaluating the prognostic potential of circulating cell-free DNA in advanced thyroid cancer". Associate Professor Matti Gild Staff Specialist | Department of Endocrinology | Royal North Shore Hospital Sydney Medical School - Northern | University of Sydney Kolling Institute of Medical Research | St Leonards I’m honoured to receive the Endocrine-Related Cancer Emerging Leader 2025 Best Paper Award for my work exploring the prognostic potential of circulating cell-free DNA in advanced thyroid cancer. In this study, we were able to demonstrate that cfDNA detection changes dynamically with treatment response, with reduced mutation detection on tyrosine kinase inhibitor therapy suggestive of strong on-target efficacy, while increasing cfDNA levels were associated with worse progression-free survival. These findings offer new insight into how cfDNA...
Endocrine-Related Cancer logo. Characterization of small intestinal neuroendocrine tumorlets. By Akitada Yogo et al. Figure 1. Characteristics of the SINTs. (A) Size of the 103 SINTs. (B) Distance from the nearby palpable SI-NET mass to the 93 SINTs that were detected on the same slide as the palpable SI-NET mass. Endocrine-Related Cancer 33, 4; 10.1530/ERC-25-0425. Published by Bioscientifica logo. 80 Years 1946-2026 Society for Endocrinology logo.
Endocrine-Related Cancer logo. OPEN FOR SUBMISSIONS 19th WorldMEN International Workshop Unmet Needs in Multiple Endocrine Neoplasia Syndromes Special Collection Collection Editors: Ana O. Hoff - Chief of Endocrine Oncology at Instituto do Cancer do Estado de São Paulo. Madson Q. Almeida - Associate Professor of Endocrinology and Metabolism, Department of Clinical Medicine, Faculty of Medicine, University of São Paulo. Maria Luisa Brandi - Professor of Endocrinology, University of San Raffaele, Milan, Italy.
Endocrine-Related Cancer logo. PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). By Virginia Corbett, Garima Gupta, and Aman Chauhan. Open Access logo. Figure 3. PRRT considerations. Endocrine-Related Cancer 33, 3; 10.1530/ERC-25-0495 Published by Bioscientifica logo. 80 Years 1946-2026 Society for Endocrinology logo.
Endocrine-Related Cancer logo. 80 Years 1946-2026 Society for Endocrinology logo. The Biology of Aging and Endocrine-Related Cancers: Shared Mechanisms and Interventions Special Collection. New Review. Ageing and pituitary neuroendocrine tumours (PitNETs): from bench to bedside. By Dario De Alcubierre et al. Graphical Abstract. doi.org/10.1530/ERC-25-0535.
Endocrine-Related Cancer logo. Establishment of patient-derived xenografts for neuroendocrine tumors in the avian embryo model. By Nilakshi Kulathunga et al. Figure 1. Establishment of human NET patient-derived xenografts (PDXs) within the avian embryo ex ovo model. (A) Flow chart of the PDX establishment procedure in the avian embryo ex ovo model. The numbers represent embryonic day of development. (B) Representative PDXs from PanNET and SI-NET primary tumors, lymph node, and liver metastasis. Top row: bright-field images. Bottom row: ultrasound B-mode images. Scale bar: 1,000 μm. (C) PDX tumor volume at the experimental endpoint, measured by ultrasound imaging. (D) Patient and NET characteristics from which tumor fragments were used to establish PDXs. PDXs were established from various tissue specimens from each patient, as indicated by the ‘tissue origin’. (E) PDX engraftment rate according to the patient’s sex, primary tumor location, grade, and tissue of origin. Endocrine-Related Cancer 33, 3; 10.1530/ERC-25-0377. Published by Bioscientifica logo. 80 Years 1946-2026 Society for Endocrinology logo.
New Review. Giant cell tumor of the sphenoid bone: a systematic literature review with illustrative cases, By Tatiana Lecot-Connan et al. Dr Fanny Chasseloup AP-HP, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse, Le Kremlin Bicêtre, France Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Le Kremlin-Bicêtre, France Emerging Leaders 2025 Special Collection. Endocrine-Related Cancer logo. 80 Years 1946-2026 Society for Endocrinology logo.
Special Collection. Advances and Innovations: The Next Chapter in Pheochromocytoma and Paraganglioma. New Research: Succinate dehydrogenase-deficient cancer cells have increased susceptibility to Ym155-induced DNA damage. Endocrine-Related Cancer logo. 80 Years 1946-2026 Society for Endocrinology logo.
Clinical and prognostic significance of parathyroid hormone-related protein in breast cancer: a systematic review and meta-analyses of observational studies in women. By Alisson Clemenceau et al. Endocrine-Related Cancer logo. Figure 1. PRISMA flow diagram. Adapted from Page et al. (51) (for more information, visit: https://www.prisma-statement.org/). Endocrine-Related Cancer 33, 3; 10.1530/ERC-25-0324. Published by Bioscientifica logo. 80 Years 1946-2026 Society for Endocrinology logo.
Endocrine-Related Cancer logo. New Guidelines. NANETS Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors. Endocrine-Related Cancer journal cover.
From Discovery Science to the Clinic - Heritable Endocrine Cancers and Related Disorder Special Collection. New Research. Comprehensive analysis of germline and somatic SDHA alterations reveals rare incidental germline variants and prognostic implications of somatic loss in breast cancer. By Henriett Butz et al. Endocrine-Related Cancer logo. 80 Years 1946-2026 Society for Endocrinology logo.
Endocrine-Related Cancer logo. New Research. Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602). By Jonathan R Strosberg et al. Published by Bioscientifica logo. 80 Years 1946-2026 Society for Endocrinology logo.
The Biology of Aging and Endocrine-Related Cancers: Shared Mechanisms and Interventions Special Collection. Endocrine-Related Cancer logo.
Endocrine-Related Cancer logo. Biology of Aging and Endocrine-Related Cancers: Shared Mechanisms and Interventions Special Collection. Adrenal tumors in the elderly. By Abel Decmann et al. Graphical Abstract. Published by Bioscientifica. 80 Years SfE logo.
Endocrine-Related Cancer. RET@Thirty: Three Decades of Remarkable Progress. Special Collection.
Endocrine-Related Cancer logo. Functional analysis of AIP variants in a cohort of neuroendocrine neoplasms. By Blanca R Carranza-Zavala et al. Figure 1. Initial assessment of AIP variants in the study cohort. (A) Coronal (left) and sagittal (right) representative gadolinium-enhanced T1-weighted preoperatory magnetic resonance images of Case 3, showing a pituitary macroadenoma. (B) Frequency of AIP variants within each clinical category included in the cohort of adult patients with NENs. (C) Schematic representation of AIP exons (top) and corresponding protein domains (bottom) displaying the VOI identified in this study. α-helix, carboxy-terminal alpha-helix; CS, Cushing’s syndrome; EO, early onset; GH, growth hormone; LB, likely benign; MEN, multiple endocrine neoplasia; MEN1, MEN type 1; MEN2A and MEN2B, MEN types 2A and 2B; MTC, medullary thyroid carcinoma; NENs, neuroendocrine neoplasms; NF1, neurofibromatosis type 1; P/LP, pathogenic and likely pathogenic; PanNEN, pancreatic neuroendocrine tumor; PHPT, primary hyperparathyroidism; PitNET, pituitary neuroendocrine tumor; PPGL, pheochromocytoma or paraganglioma; PPIase, peptidyl-prolyl cis–trans isomerase domain; TPR1, TPR2, and TPR3, tetratricopeptide repeats 1, 2, and 3; VHL, von Hippel–Lindau syndrome; VOI, variants of interest; VUS, variant of uncertain significance. Citation: Endocrine-Related Cancer 33, 1; 10.1530/ERC-25-0095. Published by Bioscientifica logo. 80 Years 1946-2026 Society for Endocrinology logo.
Endocrine-Related Cancer logo. Long-term calcitonin after thyroidectomy for medullary thyroid cancer in MEN2A. By Marijn L van den Berg et al. Figure 2. Postoperative calcitonin course during follow-up presented for each individual patient. Ctn, calcitonin; TTx, thyroidectomy; MTC, medullary thyroid cancer; ULN, upper limit of normal. Endocrine-Related Cancer 33, 1; 10.1530/ERC-25-0366. Published by Bioscientifica logo. 80 Years 1946-2026 Society for Endocrinology logo.
Emerging Leaders 2025 Special Collection. Explore the 2025 Emerging Leaders Collection.
Endocrine-Related Cancer logo. 80 Years Society for Endocrinology logo. PDF screenshot of 'Expanding horizons in Endocrine-Related Cancer: innovation, imagination, and a shared global vision' (https://doi.org/10.1530/ERC-25-0497)
Systems Biology Approaches in Hormone-Dependent Cancer Research. Themed Collection. Endocrine-Related Cancer logo. New Review: Hallmarks of disease: how tuned hierarchies of intelligent molecular neural networks (MNNs) may matter. By Hans V Westerhoff.
Endocrine-Related Cancer logo. New Associate Editor. Ilan Shimon, MD Head of the Endocrinology & Diabetes Institute at Rabin Medical Centre and Professor of Medicine at Tel Aviv University, Israel Society for Endocrinology logo.
Endocrine-Related Cancer logo. New Research. Predictors of survival outcomes in patients with neuroendocrine neoplasms: a real-world retrospective study. By Marta Laganà et al. Published by Bioscientifica. Society for Endocrinology logo.
Endocrine-Related Cancer logo. New Research: GLP1 receptor agonism alters growth and therapeutic response in prostate cancer. By Soumen Bera et al. Published by Bioscientifica logo. Society for Endocrinology logo.
Collection Curated by Prof. Karel Pacak. Incoming Editor-in-Chief of Endocrine-Related Cancer. Images of PDFs of a selection of the selected articles. Endocrine-Related Cancer logo.
Endocrine-Related Cancer logo. New Review: Towards harmonised paediatric thyroid cancer care: adult comparisons and gaps. By Michaela Kuhlen, Marina Kunstreich, and Antje Redlich. Published by bioscientifica logo. Society for Endocrinology logo.
Top left: Endocrine-Related Cancer logo. Text: Explore and contribute to expert-curated research on hormone-related cancers. Bottom right: Society for Endocrinology logo.
Headline text: Welcome our new Associate Editor... Headshot of Joakim Crona, MD, PhD Text reads: Joakim Crona, MD, PhD, Associate Professor, Uppsala University, Sweden Bottom left: Endocrine-Related Cancer logo. Bottom right: Society for Endocrinology logo.
Endocrine-Related Cancer. 2025 Best Paper Award. Bioscientifica. Society for Endocrinology.
Special Collection. Advances and Innovation: The Next Chapter in Pheochromocytoma and Paraganglioma. Endocrine-Related Cancer.
New Research: First-line lenvatinib and sorafenib in RR-DTC from a shared real-life context in Endocrine-Related Cancer. By Vincenzo Marotta et al. Published by Bioscientifica. Society for Endocrinology.
New Research: Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer in Endocrine-Related Cancer. By Takayuki Ueno et al. Figure 1. Study flow diagram. Citation: Endocrine-Related Cancer 32, 9; 10.1530/ERC-24-0353
Endocrine-Related Cancer. Exciting opportunity to join our Editorial Board. "The programme allowed me to dip my toes into the editorial side of peer review, to which I had not previously been exposed." Amy Dwyer, PhD. Current Endocrine-Related Cancer Early-Career Editor. Society for Endocrinology.
NEW RESEARCH: Anlotinib in progressive RAI-refractory differentiated thyroid cancer: long-term results and PET/CT prognostic markers in Endocrine-Related Cancer. By Di Sun et al. Published by Bioscientifica. Society for Endocrinology.
Locoregional progression and surgical indications in stage IV asymptomatic SI-NETs in Endocrine-Related Cancer. By Branislav Klimácek et al. Figure 2. Kaplan−Meier estimates of time to symptom onset in initially asymptomatic patients. A full color version of this figure is available at https://doi.org/10.1530/ERC-25-0205. Citation: Endocrine-Related Cancer 32, 8; 10.1530/ERC-25-0205 Published by Bioscientifica. Society for Endocrinology.
Register Now! 2025 Margie & Robert E. Petersen. Neuroendocrine Tumor Research Symposium. Breakthroughs today, cures tomorrow. Location: Boston, Massachusetts. Date: November 17-19.
New Research: Targeting Src tyrosine kinase to enhance radioiodide uptake in breast cancer in Endocrine-Related Cancer. By Vikki L Poole et al. Published by Bioscientifica. Society for Endocrinology. Figure 1. Phosphorylated PBF represses RAIU in breast cancer cells. (A) Left – schematic of the interaction between NIS and PBF proteins tagged at the C-terminus with the NanoLuc luciferase subunits LgBiT and SmBiT, respectively. In close proximity, LgBiT and SmBiT form a functional enzyme that uses the substrate furimazine to produce a high-intensity, luminescent signal. Created using Alphafold (59, 60) and BioRender. Right – NanoBiT analysis of NIS:PBF interaction in MCF-7 cells, with bar graph showing results at 20 min post-addition of Nano-Glo live cell assay substrate. (B) Co-immunoprecipitation assay showing PBF-HA and NIS-MYC interaction in MCF-7 breast cancer cells. (C) Schematic of PBF highlighting the overlapping phosphorylation site and endocytosis motif at the C-terminus, and the PBF-Y174A and E170_N172delinsAAA (PBF-EEN MUT) mutants. (D) Western blot showing the phosphorylation status of PBF-Y174A and PBF-EEN MUT compared with PBF-WT in MCF-7 cells. (E) Immunofluorescent images showing PBF-WT, PBF-Y174A and PBF-EEN MUT localisation in MCF-7 cells. (F) Immunofluorescent images showing subcellular localisation following the co-transfection of NIS-MYC (green) with VO, PBF-WT, PBF-Y174A or PBF-EEN MUT (red) in MCF-7 cells. Co-localisation is seen in yellow. (G) The effect of PBF and phosphomutants (Y174A/EEN-MUT) on RAIU in MCF-7 (i) and MDA-MB-231 (ii) cells transiently co-transfected with NIS-MYC. (H) The effect of PBF and phosphomutants (Y174A/EEN-MUT) on RAIU in MCF-7 cells treated with ATRA and dexamethasone. VO = vector only control. Bars = 10 μm. n = 3 for all experiments. Error bars = SEM. Significance shown compared with VO unless otherwise shown...Endocrine-Related Cancer 32, 8; 10.1530/ERC-24-0312
New Research: Heme-oxygenase-1: a key player in thyroid carcinoma development in Endocrine-Related Cancer. By Exequiel Gonzalo Alonso et al. Graphical Abstract. Published by Bioscientifica. Society for Endocrinology.
Special Collection: Pituitary Tumours: Scientific Discoveries, Clinical Advances and Contested Paradigms. Endocrine-Related Cancer. Collection Editors: Dr. Sunita M. C. De Sousa, MD, PhD Dr. Frederic Castinetti, MD, PhD Dr. Henriett Butz, MD, PhD Dr. Adrian F. Daly, MD, PhD
Targeting RET in medullary thyroid cancer in Endocrine-Related Cancer. By Kate Newbold and Leslie Cheng. This paper forms part of the themed collection RET@Thirty: Three Decades of Remarkable Progress. The Guest Editors for this collection were Tom Kurzawinski, Neil McDonald and Kate Newbold.
Follow us on LinkedIn. LinkedIn logo. Endocrine-Related Cancer logo.
Endocrine-Related Cancer. Themed Collection: Systems Biology Approaches in Hormone Dependent Cancer Research. New Review: Systems biology successes and areas for opportunity in prostate cancer in Endocrine-Related Cancer. By Michael V Orman et al.
Endocrine-Related Cancer. New Associate Editor. Professor Alfred Lam. Professor of Pathology, Griffith University, Australia. Latest Research: Rising incidence of follicular thyroid carcinoma and oncocytic carcinoma of the thyroid. By Steven Weller, Cordia Chu, and Alfred King-yin Lam
The Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors (NETs). Submissions Now Open. Proposal Due August 31, 2025. ERF Logo. NETRF logo.
New Research: DNA-PKcs inhibition as a therapeutic approach for differentiated thyroid cancer in Endocrine-Related Cancer. By Shu-Fu Lin et al. Society for Endocrinology. Published by bioscientifica.
New Review in Emerging Leaders 2025 Special Collection. Impact of treatment on quality of life in neuroendocrine neoplasm survivors in Endocrine-Related Cancer. By Roberta Modica et al. Endocrine-Related Cancer.
Endocrine-Related Cancer. Incoming Editor-in-Chief, Dr Karel Pacak. "It is a great honor to assume the role of Editor-in-Chief of Endocrine-Related Cancer, a journal fully committed to raising awareness of endocrine cancers among healthcare providers by supporting excellence in basic and clinical research, high-quality studies, and evidence-based guidelines." Published by Bioscientifica. Society for Endocrinology.
Endocrine-Related Cancer. New Open-Access Research: Plasma metabolomics for the preoperative diagnosis of parathyroid carcinoma. By Jinheng Xiao et al. Published by Bioscientifica. Society for Endocrinology.